We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec
Read MoreHide Full Article
Pacific Biosciences of California, Inc. (PACB - Free Report) recently announced the addition of the PacBio Sequel II System to inqaba biotec’s portfolio of genomics services.
inqaba biotec is the leading provider of a full range of DNA sequencing and DNA synthesis services. Pacific Biosciences has partnered with inqaba biotec to establish the latter as its first Sequel II System service provider for the entire Africa.
This development is expected to boost Pacific Biosciences’ flagship platform – the Sequel system.
More on the PacBio Sequel II System
Built on the well-established Single Molecule, Real-Time (SMRT) Sequencing technology, the Sequel II System offers highly precise long reads, with 15 times more data compared with the original Sequel System.
The PacBio Sequel II System is proficient at comprehensive variant detection, from single base changes to multi-kilobase structural variants, and can be used for a wide array of applications, including whole-genome, amplicon, and full-length transcriptome sequencing, as well as epigenetic characterization. With longer HiFi reads and higher throughput, the Sequel II System will help inqaba biotec collect not only human genomes but also those of plants and animals found in the African continent.
Customers can expect significant reduction in project costs and higher output from this system. Using data from the Sequel II System, highly accurate ethnic-specific human genome datasets can be generated that should enhance understanding of population genetics and disease response.
Recent Development
In April, the company announced collaborations with commercial, academic and government research teams that are studying the SARS-CoV-2, the virus responsible for the COVID-19 pandemic. The highly detailed long reads produced by the company’s SMRT Sequencing technology can be utilized in solving variants of the virus that exist within a single individual or across a population of patients.
Market Prospect
Per a report by AlliedMarketResearch, the global DNA sequencing market was valued at $6.24 billion in 2017 and is projected to reach $25.47 billion in 2025, at a CAGR of 19.0%. Hence, this integration comes at an ideal time.
Price Performance
In the past three months, the stock has lost 35.8% compared with 7.9% decline of its industry.
Zacks Rank and Other Key Picks
Pacific Biosciences currently has a Zacks Rank # 2 (Buy).
DexCom’s long-term earnings growth rate is estimated at 36.7%. The company presently carries a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is estimated at 10%. It currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec
Pacific Biosciences of California, Inc. (PACB - Free Report) recently announced the addition of the PacBio Sequel II System to inqaba biotec’s portfolio of genomics services.
inqaba biotec is the leading provider of a full range of DNA sequencing and DNA synthesis services. Pacific Biosciences has partnered with inqaba biotec to establish the latter as its first Sequel II System service provider for the entire Africa.
This development is expected to boost Pacific Biosciences’ flagship platform – the Sequel system.
More on the PacBio Sequel II System
Built on the well-established Single Molecule, Real-Time (SMRT) Sequencing technology, the Sequel II System offers highly precise long reads, with 15 times more data compared with the original Sequel System.
The PacBio Sequel II System is proficient at comprehensive variant detection, from single base changes to multi-kilobase structural variants, and can be used for a wide array of applications, including whole-genome, amplicon, and full-length transcriptome sequencing, as well as epigenetic characterization. With longer HiFi reads and higher throughput, the Sequel II System will help inqaba biotec collect not only human genomes but also those of plants and animals found in the African continent.
Customers can expect significant reduction in project costs and higher output from this system. Using data from the Sequel II System, highly accurate ethnic-specific human genome datasets can be generated that should enhance understanding of population genetics and disease response.
Recent Development
In April, the company announced collaborations with commercial, academic and government research teams that are studying the SARS-CoV-2, the virus responsible for the COVID-19 pandemic. The highly detailed long reads produced by the company’s SMRT Sequencing technology can be utilized in solving variants of the virus that exist within a single individual or across a population of patients.
Market Prospect
Per a report by AlliedMarketResearch, the global DNA sequencing market was valued at $6.24 billion in 2017 and is projected to reach $25.47 billion in 2025, at a CAGR of 19.0%. Hence, this integration comes at an ideal time.
Price Performance
In the past three months, the stock has lost 35.8% compared with 7.9% decline of its industry.
Zacks Rank and Other Key Picks
Pacific Biosciences currently has a Zacks Rank # 2 (Buy).
Some other top-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , DexCom (DXCM - Free Report) and Surmodics (SRDX - Free Report) .
ResMed has a projected long-term earnings growth rate of 12%. It currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DexCom’s long-term earnings growth rate is estimated at 36.7%. The company presently carries a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is estimated at 10%. It currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>